0000929638-23-002227.txt : 20230811 0000929638-23-002227.hdr.sgml : 20230811 20230811160110 ACCESSION NUMBER: 0000929638-23-002227 CONFORMED SUBMISSION TYPE: NT 20-F PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230810 FILED AS OF DATE: 20230811 DATE AS OF CHANGE: 20230811 EFFECTIVENESS DATE: 20230811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Global Cord Blood Corp CENTRAL INDEX KEY: 0001467808 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: NT 20-F SEC ACT: 1934 Act SEC FILE NUMBER: 001-34541 FILM NUMBER: 231163871 BUSINESS ADDRESS: STREET 1: 48 FL., BANK OF CHINA TOWER STREET 2: 1 GARDEN ROAD CITY: CENTRAL HONG KONG STATE: K3 ZIP: 000000 BUSINESS PHONE: 852-3605-8180 MAIL ADDRESS: STREET 1: 48 FL., BANK OF CHINA TOWER STREET 2: 1 GARDEN ROAD CITY: CENTRAL HONG KONG STATE: K3 ZIP: 000000 FORMER COMPANY: FORMER CONFORMED NAME: China Cord Blood Corp DATE OF NAME CHANGE: 20090707 NT 20-F 1 12b.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 12b-25

NOTIFICATION OF LATE FILING
SEC File Number: 001-34541
CUSIP Number:   G39342103 

(Check One):  ☐ Form 10-K ☑ Form 20-F ☐ Form 11-K  ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR
For Period Ended: March 31, 2023
☐ Transition Report on Form 10-K
☐ Transition Report on Form 20-F
☐ Transition Report on Form 11-K
☐ Transition Report on Form 10-Q
For the Transition Period Ended:
                 
 
 
 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A


Part I - Registrant Information
                 
 
 
 
 Global Cord Blood Corporation
Full Name of Registrant
 
N/A
Former Name if Applicable
 
48th Floor. Bank of China Tower
1 Garden Road
Central
Hong Kong S.A.R.
Address of Principal Executive Office (Street and Number)
 
 
 




Part II - Rules 12b-25(b) and (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

           
 
(a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
 
 
 ☐ 
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
 
 
 
(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

Part III - Narrative
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

On September 22, 2022, the Grand Court of the Cayman Islands (the “Court”) issued an order appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited, as joint provisional liquidators (the “JPLs”) of Global Cord Blood Corporation (the “Company”) pursuant to Section 104(2) of the Companies Act (as amended) of the Cayman Islands.

Since their appointment, the JPLs have furnished four reports on their work to the Court (on October 21, 2022, December 1, 2022, March 1, 2023 and June 1, 2023), copies of which are available on the Company’s website https://ir.globalcordbloodcorporation.com, as well as on the JPLs’ estate portal:  https://www.grantthornton.ca/en/service/advisory/creditor-updates/#Global-Cord-Blood-

As the JPLs’ investigations into the Company’s financial position is ongoing, the Company was unable to timely file its Annual Report on Form 20-F for the Company’s fiscal year ended March 31, 2023 (the 2023 Annal Report”) without unreasonable effort or expense. The Company cannot at this time estimate the anticipated filing date of the 2023 Annual Report.

Part IV - Other Information
(1) Name and telephone number of person to contact in regard to this notification
 


Margot MacInnis
 345
949 7100
(Name)
(Area Code)
(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). ☑ Yes ☐ No
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?   ☑ Yes ☐ No


If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

As the JPLs’ investigations into the Company’s financial position is ongoing, the Company cannot at this time estimate the extent of any change in results of operations from the fiscal year ended March 31, 2022 that would be reflected by the earnings statements to be included in the 2023 Annual Report.








Global Blood Cord Corporation
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.



Date: August 11, 2023
  


 
By: 
/S/ Margot MacInnis
 
 
Margot Macinnis
Joint Provisional Liquidator by Order of the Grand Court of the Cayman Islands